文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

过表达神经调节蛋白-1 的转基因小鼠模型神经纤维瘤-恶性外周神经鞘瘤的进展,并提示特定的染色体拷贝数变异与肿瘤发生有关。

Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.

机构信息

Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama 35294-0017, USA.

出版信息

Am J Pathol. 2013 Mar;182(3):646-67. doi: 10.1016/j.ajpath.2012.11.017. Epub 2013 Jan 13.


DOI:10.1016/j.ajpath.2012.11.017
PMID:23321323
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3586689/
Abstract

Patients with neurofibromatosis type 1 (NF1) develop benign plexiform neurofibromas that frequently progress to become malignant peripheral nerve sheath tumors (MPNSTs). A genetically engineered mouse model that accurately models plexiform neurofibroma-MPNST progression in humans would facilitate identification of somatic mutations driving this process. We previously reported that transgenic mice overexpressing the growth factor neuregulin-1 in Schwann cells (P(0)-GGFβ3 mice) develop MPNSTs. To determine whether P(0)-GGFβ3 mice accurately model human neurofibroma-MPNST progression, cohorts of these animals were monitored through death and were necropsied; 94% developed multiple neurofibromas, with 70% carrying smaller numbers of MPNSTs. Nascent MPNSTs were identified within neurofibromas, suggesting that these sarcomas arise from neurofibromas. Although neurofibromin expression was maintained, P(0)-GGFβ3 MPNSTs exhibited Ras hyperactivation, as in human NF1-associated MPNSTs. P(0)-GGFβ3 MPNSTs also exhibited abnormalities in the p16(INK4A)-cyclin D/CDK4-Rb and p19(ARF)-Mdm-p53 pathways, analogous to their human counterparts. Array comparative genomic hybridization (CGH) demonstrated reproducible chromosomal alterations in P(0)-GGFβ3 MPNST cells (including universal chromosome 11 gains) and focal gains and losses affecting 39 neoplasia-associated genes (including Pten, Tpd52, Myc, Gli1, Xiap, and Bbc3/PUMA). Array comparative genomic hybridization also identified recurrent focal copy number variations affecting genes not previously linked to neurofibroma or MPNST pathogenesis. We conclude that P(0)-GGFβ3 mice represent a robust model of neurofibroma-MPNST progression useful for identifying novel genes driving neurofibroma and MPNST pathogenesis.

摘要

患有神经纤维瘤病 1 型 (NF1) 的患者会出现良性丛状神经纤维瘤,这些肿瘤经常进展为恶性外周神经鞘瘤 (MPNST)。一种能够准确模拟人类丛状神经纤维瘤-MPNST 进展的基因工程小鼠模型将有助于确定驱动这一过程的体细胞突变。我们之前报道过,在 Schwann 细胞中过度表达生长因子神经调节蛋白-1 的转基因小鼠 (P(0)-GGFβ3 小鼠) 会发展为 MPNST。为了确定 P(0)-GGFβ3 小鼠是否准确模拟人类神经纤维瘤-MPNST 进展,对这些动物进行了死亡监测和尸检;94%的动物发展出了多发性神经纤维瘤,其中 70%的动物携带数量较少的 MPNST。在神经纤维瘤中发现了新生的 MPNST,表明这些肉瘤源自神经纤维瘤。尽管神经纤维瘤抑制蛋白的表达得以维持,但 P(0)-GGFβ3 MPNST 表现出 Ras 过度激活,类似于人类 NF1 相关的 MPNST。P(0)-GGFβ3 MPNST 还表现出 p16(INK4A)-cyclin D/CDK4-Rb 和 p19(ARF)-Mdm-p53 通路的异常,与人类对应物相似。阵列比较基因组杂交 (CGH) 显示 P(0)-GGFβ3 MPNST 细胞中存在可重复的染色体改变 (包括普遍的 11 号染色体增益) 和影响 39 个肿瘤相关基因的局灶性增益和缺失 (包括 Pten、Tpd52、Myc、Gli1、Xiap 和 Bbc3/PUMA)。阵列比较基因组杂交还鉴定出影响先前与神经纤维瘤或 MPNST 发病机制无关的基因的复发性局灶拷贝数变异。我们得出结论,P(0)-GGFβ3 小鼠代表了一种用于鉴定驱动神经纤维瘤和 MPNST 发病机制的新基因的强大的神经纤维瘤-MPNST 进展模型。

相似文献

[1]
Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.

Am J Pathol. 2013-1-13

[2]
Neuregulin-1 overexpression and Trp53 haploinsufficiency cooperatively promote de novo malignant peripheral nerve sheath tumor pathogenesis.

Acta Neuropathol. 2014-4

[3]
The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics.

Am J Pathol. 2016-3

[4]
Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.

Genes Chromosomes Cancer. 2011-8-24

[5]
Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models.

J Vis Exp. 2024-5-17

[6]
Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.

J Cancer Res Clin Oncol. 2010-3-15

[7]
Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation.

Hum Mol Genet. 2019-8-15

[8]
Frequent genomic imbalances in chromosomes 17, 19, and 22q in peripheral nerve sheath tumours detected by comparative genomic hybridization analysis.

J Pathol. 2002-5

[9]
ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.

Cell Commun Signal. 2019-7-10

[10]
Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.

Anticancer Res. 2009-4

引用本文的文献

[1]
PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.

Pharmaceuticals (Basel). 2024-5-27

[2]
Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor.

J Vis Exp. 2023-8-25

[3]
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.

Neuro Oncol. 2022-11-2

[4]
Malignant peripheral nerve sheath tumor: models, biology, and translation.

Oncogene. 2022-4

[5]
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells.

J Vis Exp. 2021-8-25

[6]
Toward Understanding the Mechanisms of Malignant Peripheral Nerve Sheath Tumor Development.

Int J Mol Sci. 2021-8-10

[7]
Translating current basic research into future therapies for neurofibromatosis type 1.

Br J Cancer. 2020-7

[8]
New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.

Genes (Basel). 2020-4-28

[9]
ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.

Cell Commun Signal. 2019-7-10

[10]
Polycomb repression regulates Schwann cell proliferation and axon regeneration after nerve injury.

Glia. 2018-10-11

本文引用的文献

[1]
Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.

Hum Mutat. 2012-3-5

[2]
Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Acta Neuropathol. 2011-12-11

[3]
Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system.

Brain Res Bull. 2011-8-10

[4]
Integrated genomic analyses of ovarian carcinoma.

Nature. 2011-6-29

[5]
Making sense of cancer genomic data.

Genes Dev. 2011-3-15

[6]
Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors.

Clin Cancer Res. 2011-1-24

[7]
Estimation of nuclear population from microtome sections.

Anat Rec. 1946-2

[8]
Somatic structural rearrangements in genetically engineered mouse mammary tumors.

Genome Biol. 2010-10-13

[9]
Cross-species genomics matches driver mutations and cell compartments to model ependymoma.

Nature. 2010-7-18

[10]
TP53 mutation analysis of malignant peripheral nerve sheath tumors.

J Neuropathol Exp Neurol. 2010-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索